Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix, Versus MenC-CRM197 Vaccine With Hiberix and Priorix in Toddlers Primed With Hib But Not MenC and to Evaluate Persistence up to 5 Years After Vaccination.

Next Previous
X
Search
Trial Profile

Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix, Versus MenC-CRM197 Vaccine With Hiberix and Priorix in Toddlers Primed With Hib But Not MenC and to Evaluate Persistence up to 5 Years After Vaccination.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; Hib vaccine conjugate; Meningococcal vaccine group C conjugate
  • Indications Haemophilus infections; Measles; Meningococcal group C infections; Mumps; Rubella
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 14 Mar 2011 Primary endpoint 'Antibody-levels' has been met
    • 05 Nov 2009 Status changed from completed to active, no longer recruiting.
    • 27 Oct 2009 Planned end date (Dec 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top